TY  - JOUR
AU  - Khattak, Muhammad A
AU  - Luke, Jason J
AU  - Long, Georgina V
AU  - Ascierto, Paolo A
AU  - Rutkowski, Piotr
AU  - Schadendorf, Dirk
AU  - Robert, Caroline
AU  - Grob, Jean-Jacques
AU  - de la Cruz Merino, Luis
AU  - Del Vecchio, Michele
AU  - Spagnolo, Francesco
AU  - Mackiewicz, Jacek
AU  - Chiarion-Sileni, Vanna
AU  - Carlino, Matteo S
AU  - Mohr, Peter
AU  - De Galitiis, Federica
AU  - Ross, Merrick I
AU  - Eroglu, Zeynep
AU  - Chen, Ke
AU  - Jiang, Ruixuan
AU  - Fukunaga-Kalabis, Mizuho
AU  - Krepler, Clemens
AU  - Eggermont, Alexander M M
AU  - Kirkwood, John M
PY  - 2022
DO  - 10.1016/j.ejca.2022.08.004
UR  - http://hdl.handle.net/10668/22180
T2  - European journal of cancer (Oxford, England : 1990)
AB  - Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) versus placebo in resected stage IIB and IIC melanoma in the phase 3 KEYNOTE-716 study. Health-related quality of life (HRQoL) results are reported. Patients were randomly...
LA  - en
KW  - Adjuvant
KW  - Immunotherapy
KW  - Melanoma
KW  - Patient-reported outcomes
KW  - Pembrolizumab
KW  - Humans
KW  - Quality of Life
KW  - Neoplasm Recurrence, Local
KW  - Melanoma
KW  - Adjuvants, Immunologic
TI  - Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
TY  - research article
VL  - 176
ER  -